
Nurix Therapeutics, Inc. (NRIX) earnings
- Healthcare
- NASDAQ
- Market cap$1.4B
Next report
2027-01-27
In 67 daysQ4 FY2026Time not announced· Expected date
- EPS consensus
- -0.46
- -0.71 – -0.154 analysts
- Revenue consensus
- $288M
Latest result
40 days ago+2664.3%Revenue Beat
Estimate recorded after the release
2026-10-12Q3 FY2026AMC
- EPS
- Reported / estimate4.73 / -0.60
- Revenue
- $673M / $24.3M
Stock reaction
-0.14%
-0.12 pts vs SPY
Session 2026-10-13
Recent quarters
Latest 2 quartersRevenue and stock reaction
| Quarter | EPSReported / estimate | RevenueReported / estimate | Reaction |
|---|---|---|---|
Q3 FY2026 2026-10-12 | 4.73 / -0.60 +887.2%†¶ | $673M / $24.3M +2664.3%¶ | -0.14% -0.12 pts vs SPY Session 2026-10-13 |
Q2 FY2026 2026-07-09 | -0.81 / -0.72 -12.0%¶ | $9.04M / $15.3M -40.9%¶ | -6.60% -7.03 pts vs SPY Session 2026-07-10 |
Reported / estimate
- Q3 FY2026 · 2026-10-12-0.14%EPS4.73 / -0.60+887.2%†¶Revenue$673M / $24.3M+2664.3%¶
- Q2 FY2026 · 2026-07-09-6.60%EPS-0.81 / -0.72-12.0%¶Revenue$9.04M / $15.3M-40.9%¶
- †Unusually large: likely a one-off gain or charge, so not comparable with consensus
- ¶Estimate recorded after the releaseNo estimate was saved before the results came out, so the surprise is measured against an estimate recorded after the release.
Reaction is the close of the reacting session versus the previous close. The gap to SPY is in percentage points.